Papageorgiou, S.; Pashley, S.L.; O’Regan, L.; Khan, S.; Bayliss, R.; Fry, A.M.
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers 2022, 14, 3452.
https://doi.org/10.3390/cancers14143452
AMA Style
Papageorgiou S, Pashley SL, O’Regan L, Khan S, Bayliss R, Fry AM.
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers. 2022; 14(14):3452.
https://doi.org/10.3390/cancers14143452
Chicago/Turabian Style
Papageorgiou, Savvas, Sarah L. Pashley, Laura O’Regan, Sam Khan, Richard Bayliss, and Andrew M. Fry.
2022. "Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer" Cancers 14, no. 14: 3452.
https://doi.org/10.3390/cancers14143452
APA Style
Papageorgiou, S., Pashley, S. L., O’Regan, L., Khan, S., Bayliss, R., & Fry, A. M.
(2022). Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers, 14(14), 3452.
https://doi.org/10.3390/cancers14143452